GPR35 is a G-Protein Receptor predominantly expressed in gut epithelium, immune cells, and nervous system that serves as a primary receptor for Kynurenic acid (KYNA), a Tryptophan metabolite produced by both host cells and gut bacteria. This receptor functions as a critical molecular translator in the microbiome-host communication axis, converting microbial metabolite signals into immune-modulatory and neuromodulatory responses that influence inflammation, gut barrier integrity, and neuroinflammation.
GPR35 is like a specialised diplomatic translator stationed at the border between two countries (the microbiome and the host). The gut bacteria speak in chemical "languages" — particularly KYNA, their diplomatic messenger molecule produced from tryptophan. When KYNA arrives at the border (the intestinal wall), GPR35 receptors read this message and translate it into actions the host government (immune and nervous systems) can understand and act upon. Sometimes the message says "stand down your border patrol" (reduce inflammation via NF-κB inhibition), other times it says "strengthen the wall" (enhance barrier function), and occasionally it sends updates to headquarters (the brain) about the state of microbial affairs. Like any good translator working at a busy border crossing, GPR35 is constantly busy in the colon where bacterial populations are densest, but it also has outposts in immune cells patrolling the area and even in brain regions monitoring the situation remotely. When this translator malfunctions — as happens with certain genetic variants — the miscommunication can lead to inflammatory chaos, like border guards overreacting because they can't understand the peaceful intentions of the neighbouring territory.
GPR35 activation initiates through multiple endogenous and synthetic ligands:
Primary Activation Pathway:
KYNA (endogenous, EC50 ~10-40 μM depending on species) → GPR35 binding → conformational change → Gα₁₃ and Gαq coupling → downstream signaling cascade
G-Protein Coupled Signaling:
graph TD
A[KYNA from gut bacteria/host metabolism] --> B[GPR35 receptor]
B --> C["Gα₁₃ activation"]
B --> D["Gαq activation"]
C --> E[RhoA pathway]
C --> F[ERK1/2 phosphorylation]
D --> G[PLC activation]
G --> H["Ca²⁺ mobilization"]
F --> I["NF-κB inhibition"]
E --> J[Cytoskeletal reorganization]
H --> K[NFAT activation]
I --> L["Reduced IL-8, TNF-α"]
J --> M[Enhanced barrier function]
K --> N[Immune cell activation modulation]
Detailed Molecular Cascade:
-
Ligand Binding Phase:
- KYNA binds to extracellular loops of GPR35 (particularly ECL2)
- Alternative ligands include zaprinast (phosphodiesterase inhibitor, EC50 ~1 μM), pamoic acid, and certain bile acids
- Lodoxamide (mast cell stabilizer) acts as species-selective agonist
-
G-Protein Activation:
- Gα₁₃ coupling → RhoA/ROCK pathway activation → actin reorganization
- Gαq coupling → phospholipase C (PLC) → IP₃ generation → intracellular Ca²⁺ release
- β-arrestin recruitment → receptor internalization and alternative signaling
-
Anti-Inflammatory Cascade:
- ERK1/2 phosphorylation → inhibition of IκB degradation → NF-κB sequestration in cytoplasm
- Reduced transcription of IL-8, TNF-α, IL-6 in intestinal epithelial cells
- SOCS3 upregulation → JAK-STAT pathway suppression
-
Barrier Function Enhancement:
- RhoA activation → increased expression of tight junction proteins (ZO-1, occludin)
- Enhanced mucin production from goblet cells
- Reduced paracellular permeability
-
Immune Cell Modulation:
- In neutrophils: reduced chemotaxis and oxidative burst
- In monocytes/macrophages: M2 polarization signals
- In T cells: potential Treg differentiation support (mechanism under investigation)
-
CNS Effects:
- GPR35 in neurons modulates glutamate release (negative modulation)
- Potential neuroprotective effects via reduced excitotoxicity
- Modulation of microglial activation state
Genetic Variants:
- Rs3749171 (T108M polymorphism) → reduced receptor function → increased IBD risk (OR 1.15-1.3)
- Ethnic variation in allele frequency (higher in European populations)
GPR35 represents a therapeutically relevant node in the microbiome-immune-brain axis central to cPNI practice:
Inflammatory Bowel Disease Context:
- The rs3749171 polymorphism is consistently associated with increased risk of Crohn's disease and ulcerative colitis in European populations
- Reduced GPR35 function → impaired KYNA anti-inflammatory signaling → chronic intestinal inflammation
- Connects to the 5 plus 2 Metamodel: disrupted communication between internal milieu (gut microbiome) and host defenses
- Clinical threshold: Faecal KYNA levels <50 μmol/L correlate with reduced mucosal GPR35 activation capacity
Dysbiosis and Barrier Dysfunction:
- Dysbiosis (particularly reduced Lactobacilli and Bifidobacteria) → decreased tryptophan conversion to KYNA → reduced GPR35 activation
- This creates a vicious cycle: low GPR35 activity → increased gut permeability → more bacterial translocation → more inflammation → more dysbiosis
- Relevant in: IBS, metabolic endotoxemia, leaky gut syndromes
- Intervention point: Psychobiotics (particularly KYNA-producing strains) + tryptophan optimization
Neuropsychiatric Connections:
- The kynurenine pathway branches: some tryptophan → KYNA (neuroprotective via GPR35), other → quinolinic acid (neurotoxic)
- In depression and anxiety: dysbiosis shifts balance toward quinolinic acid production
- GPR35 activation in brain may buffer against neuroinflammation and excitotoxicity
- Connects to selfish immune system concept: systemic inflammation hijacks tryptophan for immune purposes, starving GPR35 pathway
Evolutionary Medicine Perspective:
- GPR35 represents ancient host-microbe communication (conserved in mammals)
- Modern mismatch: antibiotic use, low-fiber diet → reduced KYNA-producing bacteria → chronic low-grade GPR35 under-activation
- This may contribute to the metaflammation underlying NCDs
Clinical Applications:
- Diagnostic: Fecal KYNA measurement (HPLC or LC-MS) in IBD patients
- Therapeutic targets:
- Probiotic interventions (Lactobacillus plantarum strains produce KYNA)
- Tryptophan supplementation (2-5g/day) in context of adequate B6
- Synthetic GPR35 agonists under development (not yet clinical)
- Personalized medicine: GPR35 genotyping in treatment-resistant IBD
Metamodel Integration:
- Location: Intestinal interface where microbiome meets host
- Communication: Molecular translation of microbial metabolites
- Timing: Circadian KYNA production varies with feeding patterns
- Quantity: Dose-dependent effects (physiological KYNA ~10-100 μM in colon)
- Primary endogenous ligand is Kynurenic acid (KYNA) at EC50 ~10-40 μM
- Highest expression in colon epithelium (>10x higher than small intestine), moderate in immune cells and select brain regions
- KYNA produced by both gut bacteria (particularly Lactobacillus spp.) and host cells via kynurenine aminotransferases
- The T108M polymorphism (rs3749171) reduces receptor function by ~60% in vitro
- GPR35 activation reduces NF-κB activity by 40-70% in intestinal epithelial cell models
- Colonic KYNA concentrations range from 50-200 μM in healthy individuals, <50 μM in active IBD
- GPR35 couples to Gα₁₃ (primary) and Gαq (secondary), plus β-arrestin recruitment
- Zaprinast is 10-40x more potent than KYNA as GPR35 agonist but lacks nutritional relevance
- GPR35 expression is upregulated 3-5x by butyrate via HDAC inhibition
- Receptor is also activated by certain bile acids (particularly lithocholic acid derivatives) at high micromolar concentrations
- GPR35 knockout mice show increased susceptibility to DSS-induced colitis
- In humans, GPR35 variants associate with coronary artery disease (possibly via platelet function modulation)
- Kynurenic acid — primary endogenous agonist produced from tryptophan metabolism
- Tryptophan — dietary precursor; tryptophan availability determines KYNA production capacity
- Kynurenine Pathway — metabolic pathway producing both GPR35 agonists (KYNA) and antagonists (quinolinic acid)
- Microbiome — gut bacteria are major KYNA producers; dysbiosis reduces GPR35 activation
- Lactobacillus plantarum — specific strain capable of high KYNA production from tryptophan
- Bifidobacteria — contribute to tryptophan metabolism and KYNA generation
- Dysbiosis — reduces KYNA-producing bacteria, lowering GPR35 signaling
- IBD — GPR35 polymorphisms increase inflammatory bowel disease risk by 15-30%
- Crohn's disease — rs3749171 variant associated with increased susceptibility
- Ulcerative Colitis — reduced GPR35 function correlates with disease severity
- NF-κB — GPR35 activation inhibits this master inflammatory transcription factor
- Neuroinflammation — GPR35 in brain modulates microglial activation and neuronal excitability
- Gut barrier — GPR35 enhances tight junction integrity via RhoA pathway
- Leaky gut — reduced GPR35 function contributes to intestinal permeability
- Butyrate — upregulates GPR35 expression via HDAC inhibition, creating synergistic barrier protection
- Short-chain fatty acids — butyrate specifically increases GPR35 receptor density
- Bacterial translocation — impaired GPR35 signaling allows increased bacterial escape across epithelium
- Blood-brain barrier — GPR35 expressed in brain endothelium may modulate BBB permeability
- TLR4 — GPR35 activation counterbalances TLR4-mediated inflammatory signals
- IL-6 — production reduced by GPR35 signaling in intestinal epithelium
- TNF-α — transcription suppressed via GPR35-mediated NF-κB inhibition
- IL-8 — neutrophil chemoattractant downregulated by GPR35 activation
- TRPV1 — co-expressed with GPR35 in sensory neurons; may modulate visceral pain
- Bile acids — secondary bile acids (lithocholic acid) can activate GPR35 at high concentrations
- TGR5 — another bile acid receptor with overlapping but distinct functions from GPR35
- Excitotoxicity — GPR35 activation in neurons reduces glutamate-mediated toxicity
- Depression — dysbiosis-driven reduction in KYNA → reduced GPR35 signaling may contribute to neuroinflammation in depression
- Metaflammation — chronic low-grade inflammation partly due to reduced GPR35 tonic signaling
- 5 plus 2 Metamodel — GPR35 exemplifies Location (gut-brain axis) and Communication (metabolite signaling)